Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rasagiline in Amyotrophic Lateral Sclerosis (ALS)
NCT01232738Phase 2Completed
- Start
- Dec 2011
- Primary completion
- May 2013
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rasagiline in amyotrophic lateral sclerosis (ALS). Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised at 12 months. Started Dec 2011; status: completed.
02
Drugs
rasagiline
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT01232738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01232738.